Glossary
Anticipatory compounding: making stock before the prescription arrives
Anticipatory compounding is preparing a limited quantity of a drug product before a valid prescription order for it arrives, on the strength of an established history of receiving such orders. It has an express federal basis at 21 U.S.C. § 353a(a)(2), which is the whole reason it is not the same thing as office use: it changes when a preparation may be made, not who may receive it. The stock stays inside the pharmacy and is still released against a prescription written for an identified individual patient.
The federal basis
Section 353a sets out two alternative ways of satisfying the same exemption. The second is the anticipatory one, and it is conditioned on history rather than on volume:
(A) is by a licensed pharmacist or licensed physician in limited quantities before the receipt of a valid prescription order for such individual patient; and (B) is based on a history of the licensed pharmacist or licensed physician receiving valid prescription orders for the compounding of the drug product, which orders have been generated solely within an established relationship
Two things are doing the work. The permission is retrospective — it is earned by orders already received for that drug product, not by an expectation of future demand. And it sits underneath the section’s opening condition, which still requires the product be compounded for an identified individual patient on the receipt of a valid prescription order. The subsection moves the moment of compounding; it does not remove the prescription.
The condition state rules attach
State boards generally restate the history requirement and add what has to be true of the stock while it waits. North Carolina states the release condition in a single clause:
Any compounded drug preparation prepared in anticipation of a prescription order shall not be dispensed until the pharmacy receives a valid prescription order for an individual patient.
Georgia’s rule conditions the practice on "a history of receiving valid prescription drug orders within an established pharmacist/patient/prescriber relationship," requires the pharmacy to keep the resulting prescriptions on file, and requires anticipatory preparations to be labelled with the drug name, the date of compounding and the beyond-use date. Louisiana’s definition of compounding reaches preparations made "in anticipation of prescription orders to be received … based on routine, regularly observed prescribing patterns," and its rules require excess preparation to be labelled to its formula, lot number and estimated beyond-use date.
Why it is not office use
The two get treated as one arrangement, and they are answering different questions. Anticipatory compounding is a permission about timing: the preparation is made early and stays in the pharmacy. Office use is a permission about destination: non-patient-specific stock leaves the pharmacy for a prescriber’s cabinet, with no patient identified at all.
North Carolina’s rule makes the separation structural — the anticipatory permission and the office-use provision are different subsections, and the anticipatory one ends with the sentence quoted above. That sentence is the dividing line, and it is why anticipatory authority cannot be read as authority to supply a practice.
The two are compared in full, with the state texts side by side, in anticipatory compounding vs office use. The condition both of them run into is the patient-specific prescription requirement.